Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis

NCT06400303 is registered in ClinicalTrials.gov with Kyverna Therapeutics as lead sponsor.

NCT NCT06400303
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06400303 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
KYSA-5: A Phase 1/2, Open-Label, Multicentre Study of KYV 101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor T Cell (CD19 CAR T) Therapy, in Subjects With Systemic Sclerosis
Lead sponsor
Kyverna Therapeutics
Phase
Phase 1/2
Overall status
Terminated
Start date
August 6, 2024
Completion date
June 16, 2026
Enrollment
3 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

systemic sclerosis, systemic sclerosis - 2013 acr/eular classification criteria, systemic sclerosis - diffuse cutaneous